Evidence map›Paper›PMID 37993710›Full record

ArticleNature2024

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.

Ayijiang Yisimayi, Weiliang Song, Jing Wang, Fanchong Jian, Yuanling Yu, Xiaosu Chen, Yanli Xu, Sijie Yang, Xiao Niu, Tianhe Xiao and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed
48.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 250 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 1 country.

Ayijiang Yisimayi *Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.ORCID 0000-0003-0648-1864
Weiliang Song *Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.
Jing Wang *Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.ORCID 0000-0002-9084-9985
Fanchong Jian *Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.ORCID 0000-0001-8703-3507
Yuanling Yu *Changping Laboratory, Beijing, P. R. China.
Xiaosu Chen *Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Yanli XuBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Sijie YangBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.ORCID 0009-0001-9834-4340
Xiao NiuBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.
Tianhe XiaoBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.
Jing WangChangping Laboratory, Beijing, P. R. China.
Lijuan ZhaoChangping Laboratory, Beijing, P. R. China.
Haiyan SunChangping Laboratory, Beijing, P. R. China.
Ran AnChangping Laboratory, Beijing, P. R. China.
Na ZhangChangping Laboratory, Beijing, P. R. China.
Yao WangChangping Laboratory, Beijing, P. R. China.
Peng WangChangping Laboratory, Beijing, P. R. China.
Lingling YuChangping Laboratory, Beijing, P. R. China.
Zhe LvSinovac Biotech, Beijing, P. R. China.
Qingqing GuChangping Laboratory, Beijing, P. R. China.ORCID 0000-0001-5805-6419
Fei ShaoChangping Laboratory, Beijing, P. R. China.
Ronghua JinBeijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.ORCID 0000-0001-8496-172X
Zhongyang ShenOrgan Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, P. R. China.ORCID 0000-0003-0045-4355
Xiaoliang Sunney XieBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China.ORCID 0000-0001-9281-5239
Youchun WangChangping Laboratory, Beijing, P. R. China.ORCID 0000-0001-9769-5141
Yunlong CaoBiomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.ORCID 0000-0001-5918-1078
Peking University · CNCapital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNNankai University · CNSinovac Biotech · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continuing emergence of SARS-CoV-2 variants highlights the need to update COVID-19 vaccine compositions. However, immune imprinting induced by vaccination based on the ancestral (hereafter referred to as WT) strain would compromise the antibody response to Omicron-based boosters

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunization, SecondaryImmunologic MemorySARS-CoV-2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingEpitopes, B-LymphocyteHumansMiceMutationAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopes, B-Lymphocyte

Identifiers

PMID37993710
PMCPMC10764275
OpenAlexW4388897344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.